Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 29, 2019 - Issue 2
Submit an article Journal homepage
2,357
Views
54
CrossRef citations to date
0
Altmetric
Review

Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)

Xingrui HeKey Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, ChinaView further author information
,
Xiabin ChenKey Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, ChinaView further author information
,
Hancheng ZhangDrug Discovery, Hangzhou Innogate Pharma Co., Ltd, Hangzhou, Zhejiang Province, ChinaView further author information
,
Tian XieKey Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttp://orcid.org/0000-0001-7066-1443View further author information
ORCID Icon &
Xiang-Yang YeKey Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttp://orcid.org/0000-0003-3739-0930View further author information
ORCID Icon
Pages 137-149 | Received 19 Nov 2018, Accepted 03 Jan 2019, Published online: 22 Jan 2019

Citations (54)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Stella X. Chen, Charlotte Greif, Ruby S. Gibson, Martina L. Porter & Alexa B. Kimball. (2022) Advances in biologic and small molecule therapies for hidradenitis suppurativa. Expert Opinion on Pharmacotherapy 23:8, pages 959-978.
Read now
Felix Gonzalez Lopez de Turiso & Kevin Guckian. (2022) Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021). Expert Opinion on Therapeutic Patents 32:4, pages 365-379.
Read now
Chengjuan Chen, Dianxiang Lu, Tao Sun & Tiantai Zhang. (2022) JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present). Expert Opinion on Therapeutic Patents 32:3, pages 225-242.
Read now
Filip Machaj, Jakub Rosik, Bartosz Szostak & Andrzej Pawlik. (2020) The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery. Expert Opinion on Drug Discovery 15:1, pages 85-99.
Read now
Jing Wu, Zhaohua Zhu, Qinghong Yu & Changhai Ding. (2019) Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials. Expert Opinion on Investigational Drugs 28:12, pages 1113-1123.
Read now

Articles from other publishers (49)

Silvana LeitBhaskar SrivastavaNathan E. GenungJoshua J. McElweeDenise LevasseurScott D. Edmondson. 2023. 2023 Medicinal Chemistry Reviews. 2023 Medicinal Chemistry Reviews 157 185 .
Eric Breinlinger, Stacy Van Epps, Michael Friedman, Maria Argiriadi, Ellen Chien, Gekleng Chhor, Marlon Cowart, Theresa Dunstan, Candace Graff, David Hardee, J. Martin Herold, Andrew Little, Richard McCarthy, Julie Parmentier, Matthew Perham, Wei Qiu, Michael Schrimpf, Thomas Vargo, Matthew P. Webster, Fei Wu, Dawn Bennett & Jeremy Edmunds. (2023) Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712. Journal of Medicinal Chemistry 66:20, pages 14335-14356.
Crossref
Celia X.-J. Chen, Wei Zhang, Shulan Qu, Fucan Xia, Yidong Zhu & Bo Chen. (2023) A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways. Cell Communication and Signaling 21:1.
Crossref
Hongda Li, Honglei Wang, Guizhi Qiao, Yongxia Liu, Furen Zhang & Futang Pan. (2023) Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature. International Immunopharmacology 122, pages 110591.
Crossref
Silvana Leit, Jeremy Greenwood, Samantha Carriero, Sayan Mondal, Robert Abel, Mark Ashwell, Heather Blanchette, Nicholas A. Boyles, Mark Cartwright, Alan Collis, Shulu Feng, Phani Ghanakota, Geraldine C. Harriman, Vinayak Hosagrahara, Neelu Kaila, Rosanna Kapeller, Salma B. Rafi, Donna L. Romero, Paul M. Tarantino, Jignesh Timaniya, Angela V. Toms, Ronald T. Wester, William Westlin, Bhaskar Srivastava, Wenyan Miao, Peter Tummino, Joshua J. McElwee, Scott D. Edmondson & Craig E. Masse. (2023) Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279. Journal of Medicinal Chemistry 66:15, pages 10473-10496.
Crossref
Lidan Deng, Li Wan, Tingting Liao, Lin Wang, Jie Wang, Xianbo Wu & Jianyou Shi. (2023) Recent progress on tyrosine kinase 2 JH2 inhibitors. International Immunopharmacology 121, pages 110434.
Crossref
Kuojun Zhang, Ke Ye, He Tang, Zhihao Qi, Tianyu Wang, Jie Mao, Xiangyu Zhang & Sheng Jiang. (2023) Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors. Journal of Medicinal Chemistry 66:7, pages 4378-4416.
Crossref
Nathanael A. Caveney, Robert A. Saxton, Deepa Waghray, Caleb R. Glassman, Naotaka Tsutsumi, Stevan R. Hubbard & K. Christopher Garcia. (2023) Structural basis of Janus kinase trans-activation. Cell Reports 42:3, pages 112201.
Crossref
Qian Ding, Wei Hu, Ran Wang, Qinyan Yang, Menglin Zhu, Meng Li, Jianghong Cai, Peter Rose, Jianchun Mao & Yi Zhun Zhu. (2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduction and Targeted Therapy 8:1.
Crossref
Lluís Rusiñol & Luis Puig. (2023) Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International Journal of Molecular Sciences 24:4, pages 3391.
Crossref
Jun-ya Kato, Shigeru Korenaga & Masaru Iwakura. (2023) Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor. Bioorganic & Medicinal Chemistry Letters 79, pages 129083.
Crossref
Jiadong Yu, Qixiang Zhao, Xiaoyan Wang, Hong Zhou, Jing Hu, Linna Gu, Yawen Hu, Fanlian Zeng, Fulei Zhao, Chengcheng Yue, Pei Zhou, Guolin Li, Ya Li, Wenling Wu, Yifan Zhou & Jiong Li. (2022) Pathogenesis, multi-omics research, and clinical treatment of psoriasis. Journal of Autoimmunity 133, pages 102916.
Crossref
Fei Liu, Bin Wang, Yanlong Liu, Wei Shi, Xujing Tang, Xiaojin Wang, Zhongyuan Hu, Ying Zhang, Yahui Guo, Xiayun Chang, Xiangyi He, Hongjiang Xu & Ying He. (2022) Novel TYK2 Inhibitors with an N -(Methyl- d 3 )pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases . ACS Medicinal Chemistry Letters 13:11, pages 1730-1738.
Crossref
L. Zhang, L. Guo, L. Wang & X. Jiang. (2022) The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – A network meta‐analysis. Journal of the European Academy of Dermatology and Venereology 36:11, pages 1937-1946.
Crossref
Xiangjie Chen, Qiuyu Wu, Xinhua Cao, Yunshan Yang, Zheng Gong, Tengfei Ren, Qian Du, Yukang Yuan, Yibo Zuo, Ying Miao, Jiuyi He, Caixia Qiao, Zhijin Zheng, Tingting Zhang, Yang Xu, Depei Wu, Qiao Wang, Lin Huang, Zhijun Xie, Haitao Lv, Jun Wang, Fangyuan Gong, Zhichun Liu, Chengping Wen & Hui Zheng. (2022) Menthone inhibits type-I interferon signaling by promoting Tyk2 ubiquitination to relieve local inflammation of rheumatoid arthritis. International Immunopharmacology 112, pages 109228.
Crossref
Ana Maria Lé, Luis Puig & Tiago Torres. (2022) Deucravacitinib for the Treatment of Psoriatic Disease. American Journal of Clinical Dermatology 23:6, pages 813-822.
Crossref
Silvana Leit, Jeremy R. Greenwood, Sayan Mondal, Samantha Carriero, Markus Dahlgren, Geraldine C. Harriman, Joshua J. Kennedy-Smith, Rosana Kapeller, Jon P. Lawson, Donna L. Romero, Angela V. Toms, Mee Shelley, Ronald T. Wester, William Westlin, Joshua J. McElwee, Wenyan Miao, Scott D. Edmondson & Craig E. Masse. (2022) Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis. Bioorganic & Medicinal Chemistry Letters 73, pages 128891.
Crossref
Lin Shang, Jiali Cao, Siqi Zhao, Jingya Zhang & Yanling He. (2022) TYK2 in Immune Responses and Treatment of Psoriasis. Journal of Inflammation Research Volume 15, pages 5373-5385.
Crossref
Yu Zhou, Xin Li, Ru Shen, Xiangzhu Wang, Fan Zhang, Suxing Liu, Di Li, Jian Liu, Puhui Li, Yinfa Yan, Ping Dong, Zhigao Zhang, Heping Wu, Linghang Zhuang, Rasheduzzaman Chowdhury, Matthew Miller, Mena Issa, Yuchang Mao, Hongli Chen, Jun Feng, Jing Li, Chang Bai, Feng He & Weikang Tao. (2022) Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways. Frontiers in Immunology 13.
Crossref
Ole Haagen Nielsen, Theresa Louise Boye, Deepavali Chakravarti & John Gubatan. (2022) Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends in Pharmacological Sciences 43:5, pages 424-436.
Crossref
Christine E. Jo, Melinda Gooderham & Jennifer Beecker. (2021) TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. International Journal of Dermatology 61:2, pages 139-147.
Crossref
WooChan Kim, Sun-Mi Lee, Pyeong-Hwa Jeong, Jae-Hoon Jung & Yong-Chul Kim. (2022) Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors. Bioorganic & Medicinal Chemistry Letters 55, pages 128451.
Crossref
Thomas Linden, Frank Hanses, Daniel Domingo-Fernández, Lauren Nicole DeLong, Alpha Tom Kodamullil, Jochen Schneider, Maria J.G.T. Vehreschild, Julia Lanznaster, Maria Madeleine Ruethrich, Stefan Borgmann, Martin Hower, Kai Wille, Torsten Feldt, Siegbert Rieg, Bernd Hertenstein, Christoph Wyen, Christoph Roemmele, Jörg Janne Vehreschild, Carolin E.M. Jakob, Melanie Stecher, Maria Kuzikov, Andrea Zaliani & Holger Fröhlich. (2021) Machine Learning Based Prediction of COVID-19 Mortality Suggests Repositioning of Anticancer Drug for Treating Severe Cases. Artificial Intelligence in the Life Sciences 1, pages 100020.
Crossref
A. E. Sinotsko, A. V. Bespalov, N. V. Pashchevskaya, V. V. Dotsenko, N. A. Aksenov & I. V. Aksenova. (2021) N,N′-Diphenyldithiomalonodiamide: Structural Features, Acidic Properties, and In Silico Estimation of Biological Activity. Russian Journal of General Chemistry 91:11, pages 2136-2150.
Crossref
Kajal Sharma, Shalki Choudhary & Om Silakari. (2021) Portraying molecular modulation and therapeutic aspects of psoriasis: Retrospection and current status. Journal of Molecular Structure 1243, pages 130770.
Crossref
Stefania Gallucci, Sowmya Meka & Ana M. Gamero. (2021) Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. Cytokine 146, pages 155633.
Crossref
Sylwia Słuczanowska-Głąbowska, Anna Ziegler-Krawczyk, Kamila Szumilas & Andrzej Pawlik. (2021) Role of Janus Kinase Inhibitors in Therapy of Psoriasis. Journal of Clinical Medicine 10:19, pages 4307.
Crossref
Maciej Gonciarz, Katarzyna Pawlak-Buś, Piotr Leszczyński & Witold Owczarek. (2021) TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy.
Crossref
Dominika Hromadová, Dirk Elewaut, Robert D. Inman, Birgit Strobl & Eric Gracey. (2021) From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases. Frontiers in Genetics 12.
Crossref
James T. Rosenbaum, Christina A. Harrington, Robert P. Searles, Suzanne S. Fei, Amr Zaki, Sruthi Arepalli, Michael A. Paley, Lynn M. Hassman, Albert T. Vitale, Christopher D. Conrady, Puthyda Keath, Claire Mitchell, Lindsey Watson, Stephen R. Planck, Tammy M. Martin & Dongseok Choi. (2021) Identifying RNA Biomarkers and Molecular Pathways Involved in Multiple Subtypes of Uveitis. American Journal of Ophthalmology 226, pages 226-234.
Crossref
Jie-Hui Zhang, Cheng-Lin Pan, Huan-Huan Zhang, Peng-Fei Xu & Yong-Chun Luo. (2021) Sc(OTf) 3 catalyzed [3 + 2]-annulation reaction of donor–acceptor aziridines with methylene exo -glycals: synthesis of chiral carbohydrate-spiro-heterocycles . Organic Chemistry Frontiers 8:10, pages 2203-2207.
Crossref
Przemysław J. Kotyla, Małgorzata Engelmann, Joanna Giemza-Stokłosa, Bartosz Wnuk & Md Asiful Islam. (2021) Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?. International Journal of Molecular Sciences 22:5, pages 2449.
Crossref
Nhan Van Tran, Le Tuan Anh Nguyen, Kah Wai Lim & Anh Tuân Phan. (2021) Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides. ImmunoHorizons 5:2, pages 70-80.
Crossref
Andrea Poelzl, Caroline Lassnig, Simone Tangermann, Dominika Hromadová, Ursula Reichart, Riem Gawish, Kristina Mueller, Richard Moriggl, Andreas Linkermann, Martin Glösmann, Lukas Kenner, Mathias Mueller & Birgit Strobl. (2020) TYK2 licenses non-canonical inflammasome activation during endotoxemia. Cell Death & Differentiation 28:2, pages 748-763.
Crossref
Chunjian Liu, James Lin, Charles Langevine, Daniel Smith, Jianqing Li, John S. Tokarski, Javed Khan, Max Ruzanov, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, Kathleen M. Gillooly, David Shuster, Yifan Zhang, Anil Thankappan, Kim W. McIntyre, Charu Chaudhry, Paul A. Elzinga, Manoj Chiney, Anjaneya Chimalakonda, Louis J. Lombardo, John E. Macor, Percy H. Carter, James R. Burke & David S. Weinstein. (2020) Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. Journal of Medicinal Chemistry 64:1, pages 677-694.
Crossref
Ma-Li Wong, Mauricio Arcos-Burgos, Sha Liu, Alice W. Licinio, Chenglong Yu, Eunice W.M. Chin, Wei-Dong Yao, Xin-Yun Lu, Stefan R. Bornstein & Julio Licinio. (2021) Rare Functional Variants Associated with Antidepressant Remission in Mexican-Americans. Journal of Affective Disorders 279, pages 491-500.
Crossref
Vamshi Krishna Rapalli, Tejashree Waghule, Srividya Gorantla, Sunil Kumar Dubey, Ranendra Narayan Saha & Gautam Singhvi. (2020) Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems. Drug Discovery Today 25:12, pages 2212-2226.
Crossref
Brian S. Gerstenberger, Catherine Ambler, Eric P. Arnold, Mary-Ellen Banker, Matthew F. Brown, James D. Clark, Alpay Dermenci, Martin E. Dowty, Andrew Fensome, Susan Fish, Matthew M. Hayward, Martin Hegen, Brett D. Hollingshead, John D. Knafels, David W. Lin, Tsung H. Lin, Dafydd R. Owen, Eddine Saiah, Raman Sharma, Felix F. Vajdos, Li Xing, Xiaojing Yang, Xin Yang & Stephen W. Wright. (2020) Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry 63:22, pages 13561-13577.
Crossref
Alexandra Coomans de Brachène, Angela Castela, Anne Op de Beeck, Raghavendra G. Mirmira, Lorella Marselli, Piero Marchetti, Craig Masse, Wenyan Miao, Silvana Leit, Carmella Evans‐Molina & Decio L. Eizirik. (2020) Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta‐cell protection in type 1 diabetes. Diabetes, Obesity and Metabolism 22:10, pages 1827-1836.
Crossref
Brian S. Gerstenberger, Mary Ellen Banker, James D. Clark, Martin E. Dowty, Andrew Fensome, Roger Gifford, Matthew C. Griffor, Martin Hegen, Brett D. Hollingshead, John D. Knafels, Tsung H. Lin, James F. Smith & Felix F. Vajdos. (2020) Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. Scientific Reports 10:1.
Crossref
Pengfei Xu, Pei Shen, Bin Yu, Xi Xu, Raoling Ge, Xinying Cheng, Qiuyu Chen, Jinlei Bian, Zhiyu Li & JuBo Wang. (2020) Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. European Journal of Medicinal Chemistry 192, pages 112155.
Crossref
Yusuke Sasaki, Hidekazu Tokuhara, Yusuke Ohba, Atsutoshi Okabe, Masaharu Nakayama, Hideyuki Nakagawa, Robert Skene, Isaac Hoffman, Hua Zou & Masato Yoshida. (2020) Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic Tyk2 inhibitors. Bioorganic & Medicinal Chemistry Letters 30:5, pages 126963.
Crossref
Amanda Kvist-Hansen, Peter Riis Hansen & Lone Skov. (2019) Systemic Treatment of Psoriasis with JAK Inhibitors: A Review. Dermatology and Therapy 10:1, pages 29-42.
Crossref
Anzhelika Karjalainen, Stephen Shoebridge, Milica Krunic, Natalija Simonović, Graham Tebb, Sabine Macho-Maschler, Birgit Strobl & Mathias Müller. (2020) TYK2 in Tumor Immunosurveillance. Cancers 12:1, pages 150.
Crossref
Katharina Wöss, Natalija Simonović, Birgit Strobl, Sabine Macho-Maschler & Mathias Müller. (2019) TYK2: An Upstream Kinase of STATs in Cancer. Cancers 11:11, pages 1728.
Crossref
Yu Chang, Shilin Xu & Ke Ding. (2019) Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases. Journal of Medicinal Chemistry 62:20, pages 8951-8952.
Crossref
Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S. Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, David Shuster, Kathleen Gillooly, Xiaoxia Yang, Elizabeth Heimrich, Kim W. McIntyre, Charu Chaudhry, Javed Khan, Max Ruzanov, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Huadong Sun, Christine Huang, Celia D’Arienzo, Nelly Aranibar, Manoj Chiney, Anjaneya Chimalakonda, William J. Pitts, Louis Lombardo, Percy H. Carter, James R. Burke & David S. Weinstein. (2019) Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. Journal of Medicinal Chemistry 62:20, pages 8973-8995.
Crossref
Hans O. Kalkman. (2019) Novel Treatment Targets Based on Insights in the Etiology of Depression: Role of IL-6 Trans-Signaling and Stress-Induced Elevation of Glutamate and ATP. Pharmaceuticals 12:3, pages 113.
Crossref
Gaspard Kerner, Noe Ramirez-AlejoYoann SeeleuthnerRui YangMasato OgishiAurélie CobatEtienne PatinLluis Quintana-Murci, Stéphanie Boisson-DupuisJean-Laurent Casanova & Laurent Abel. (2019) Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry . Proceedings of the National Academy of Sciences 116:21, pages 10430-10434.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.